Prognostic value of Lynch syndrome, BRAF V600E , and RAS mutational status in dMMR / MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
Cancer Medicine · 2023
DOI: 10.1002/cam4.6223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Koen Zwart und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Current knowledge on prognostic biomarkers (especially BRAF V600E / RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with proficient mismatch repair (pMMR) tumors. It is uncertain whether these biomarkers have the same prognostic value in mCRC patients with deficient mismatch repair (dMMR) tumors.
Methods
This observational cohort study combined a population‐based Dutch cohort (2014–2019) and a large French multicenter cohort (2007–2017). All mCRC patients with a histologically proven dMMR tumor were included.
Results
In our real‐world data cohort of 707 dMMR mCRC patients, 438 patients were treated with first‐line palliative systemic chemotherapy. Mean age of first‐line treated patients was 61.9 years, 49% were male, and 40% had Lynch syndrome. BRAF V600E mutation was present in 47% of tumors and 30% harbored a RAS mutation. Multivariable regression analysis on OS showed significant hazard rates (HR) for known prognostic factors as age and performance status, however showed no significance for Lynch syndrome (HR: 1.07, 95% CI: 0.66–1.72), BRAF V600E mutational status (HR: 1.02, 95% CI: 0.67–1.54), and RAS mutational status (HR: 1.01, 95% CI: 0.64–1.59), with similar results for PFS.
Conclusion
BRAF V600E and RAS mutational status are not associated with prognosis in dMMR mCRC patients, in contrast to pMMR mCRC patients. Lynch syndrome is also not an independent prognostic factor for survival. These findings underline that prognostic factors of patients with dMMR mCRC are different of those with pMMR, which could be taken into consideration when prognosis is used for clinical decision‐making in dMMR mCRC patients and underline the complex heterogeneity of mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Medical Oncology, Équipe Instabilité des Microsatellites et Cancer, Équipe Labellisée par la Ligue Nationale Contre le Cancer et SIRIC CURAMUS, Centre de recherche Saint Antoine, Hôpital Saint-Antoine, AP-…
- Gastroenterology Department, Saint Louis Hospital, AP-HP, University of Paris, Paris, France.
- Gastroenterology Department, Avicenne Hospital, Bobigny, France.
- Medical Oncology Department, Léon Bérard Center, Lyon, France.
ORCID-Profile: Koen Zwart, Christelle de la Fouchardiére, David Sefrioui, G Emerens Wensink, David Tougeron, Jeanine M L Roodhart
Zitieren
APA
Zwart, K., van der Baan, F. H., Cohen, R., Aparicio, T., de la Fouchardiére, C., Lecomte, T., Punt, C. J. A., Sefrioui, D., Verheijden, R. J., Vink, G. R., Wensink, G. E., Zaanan, A., Koopman, M., Tougeron, D., & Roodhart, J. M. L. (2023). Prognostic value of Lynch syndrome, BRAF V600E , and RAS mutational status in dMMR / MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts. Cancer Medicine. https://doi.org/10.1002/cam4.6223
Vancouver
Zwart K, van der Baan FH, Cohen R, Aparicio T, de la Fouchardiére C, Lecomte T, et al. Prognostic value of Lynch syndrome, BRAF V600E , and RAS mutational status in dMMR / MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts. Cancer Medicine. 2023. doi:10.1002/cam4.6223
BibTeX
@article{Zwart2023,
author = {Zwart, Koen and van der Baan, Frederieke H and Cohen, Romain and Aparicio, Thomas and de la Fouchardiére, Christelle and Lecomte, Thierry and Punt, Cornelis J A and Sefrioui, David and Verheijden, Rik J and Vink, Geraldine R and Wensink, G Emerens and Zaanan, Aziz and Koopman, Miriam and Tougeron, David and Roodhart, Jeanine M L},
title = {Prognostic value of Lynch syndrome, BRAF V600E , and RAS mutational status in dMMR / MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6223}
}
EUVIMED